Showing 7051-7060 of 8649 results for "".
- BostonSight Publishes Study Highlighting Prose Lens Utilization for Drug Deliveryhttps://modernod.com/news/bostonsight-publishes-study-highlighting-prose-lens-utilization-for-drug-delivery/2482555/BostonSight announced it has published a study: “
- Bausch + Lomb’s Recycling Programs Collect Over 94 Million Units of Eye Care Waste in the UShttps://modernod.com/news/bausch-lombs-recycling-programs-collect-over-94-million-units-of-eye-care-waste-in-the-us/2482541/Bausch + Lomb announced a milestone in its sustainability efforts—the company's exclusive recycling initiatives, ONE by ONE Recycling and Biotrue Eye Care Recycling programs, have successfully collected a total of 94,119,275 units of used contact lenses, eye care, and lens care material
- MediPrint Ophthalmics Unveils Phase 2b Trial Results for Drug-Eluting Contact Lens in Glaucoma Treatmenthttps://modernod.com/news/mediprint-ophthalmics-unveils-phase-2b-trial-results-for-drug-eluting-contact-lens-in-glaucoma-treatment/2482539/MediPrint Ophthalmics announced positive results from its phase 2b clinical trial of its 3D-printed, drug-eluting contact lens LL-BMT1. The results, presented by Ian Ben Gaddie, OD, FAAO, at the Ameri
- Ocular Therapeutix Names Namrata Saroj as Chief Business Officerhttps://modernod.com/news/ocular-therapeutix-names-namrata-saroj-as-chief-business-officer/2482536/Ocular Therapeutix announced that Namrata Saroj, OD, has joined the company as Chief Business Officer (CBO). Dr. Saroj, who has been consulting with Ocular since February 2024, brings extensive experience in clinical development and commercialization in ophthalmology. She cont
- Neurotech Provides Update on BLA for NT-501 as a Treatment for Macular Telangiectasia Type 2https://modernod.com/news/neurotech-provides-update-on-bla-for-nt-501-as-a-treatment-for-macular-telangiectasia-type-2/2482531/Neurotech Pharmaceuticals announced that the FDA has extended the Prescription Drug User Fee Act (PDUFA) goal date by 3 months to allow time required for the FDA to review additional data provided by the company in response to recent requests from the FDA. Originally set for December 17
- FELIQS Receives FDA Fast Track Designation for FLQ-101, a First-in-Class Small Molecule to Prevent Retinopathy of Prematurityhttps://modernod.com/news/feliqs-receives-fda-fast-track-designation-for-flq-101-a-first-in-class-small-molecule-to-prevent-retinopathy-of-prematurity/2482526/FELIQS announced that the US Food and Drug Administration (FDA) has granted its lead asset, FLQ-101, Fast Track designation for the prevention of retinopathy of prematurity (ROP). The company plans to conduct a Phase1b/2 study of FLQ-101 (tROPhy-1 study) both in the United States and Ja
- New Report by Contact Lens Institute Reveals Strategies to Enhance Contact Lens Retentionhttps://modernod.com/news/new-report-by-contact-lens-institute-reveals-strategies-to-enhance-contact-lens-retention/2482520/The Contact Lens Institute (CLI) has just published an in-depth, data-driven report titled “Disrupting the Dropout Dilemma: Practical Steps to Keep Patients in Contact Lenses.” Aimed at assisting eye care
- Science Corporation: PRIMA Clinical Trials Show Restoration of "Form Vision"https://modernod.com/news/science-corporation-announces-breakthrough-in-retinal-implant-technology-prima-clinical-trials-show-restoration-of-form-vision/2482509/Science Corporation, a developer in brain-computer interface (BCI) technology, has announced preliminary results from clinical trials of its PRIMA retina implant. This technology has demonstrated the ability to restore what the company is calling 'form vision' in patients suffer
- Haag-Streit to Host "Biometry Focus Month 2024" with Weekly Webinars in Novemberhttps://modernod.com/news/haag-streit-to-host-biometry-focus-month-2024-with-weekly-webinars-in-november/2482492/Haag-Streit has announced the return of "Biometry Focus Month 2024" in November. The event will feature a series of live webinars every Thursday from November 7 to November 28, 2024. Each session will address critical topics in biometry, offering cataract and refractive surgeons ke
- Oculis to Provide Update on DIAMOND Phase 3 Program for OCS-01 Eye Drops at Innovate Retina and Eyecelerator 2024https://modernod.com/news/oculis-to-provide-update-on-diamond-phase-3-program-for-ocs-01-eye-drops-at-innovate-retina-and-eyecelerator-2024/2482488/Oculis announced an update on its DIAMOND phase 3 program for OCS-01, a high-concentration dexamethasone eye drop formulated with OPTIREACH technology for the treatment for diabetic macular edema (DME). David Eichenbaum, MD, an expert in retina diseases, will present new insig